Navigation Links
Insmed CEO Issues Statement on White House FY09 Budget and FDA Statements on Follow-On Biologics
Date:2/5/2008

to differ materially from those anticipated by the forward-looking statements. The risks and uncertainties include, without limitation, risks that product candidates may fail in the clinic or may not be successfully marketed or manufactured, we may lack financial resources to complete development of product candidates, the FDA may interpret the results of studies differently than us, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends, our entrance into the follow on biologics market may be unsuccessful, our common stock could be delisted from the Nasdaq Global Market and other risks and challenges detailed in our filings with the U.S. Securities and Exchange Commission, including our Quarterly Report on Form 10-Q for the quarter ended September 30, 2007. Readers are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release. We undertake no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.

Investor Relations Contact:

Brian Ritchie - FD

212-850-5683

brian.ritchie@fd.com

Corporate Communications Contact:

John Procter - Gibraltar Associates

202-879-5808

jprocter@gibraltar-llc.com


'/>"/>
SOURCE Insmed Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Insmed President Interviewed for Follow-On Biologics Podcast: Insmed Inc. President Steve Glover Discusses Safe and Effective Biologic Therapies and Reduced Costs with The American Magazine
2. Insmed to Appeal Delisting Notification From Nasdaq
3. Insmed Awarded $2.1 Million by Muscular Dystrophy Association
4. Insmed Appoints Dennis M. Lanfear to Board Of Directors
5. Baxter Issues Urgent Nationwide Voluntary Recall of Heparin 1,000 Units/mL 10 and 30mL Multi-Dose Vials
6. FDA Issues Approvable Letter for LUVOX(R) CR (Fluvoxamine Maleate) Extended-Release Capsules for the Treatment of Social Anxiety Disorder (SAD) and Obsessive Compulsive Disorder (OCD)
7. Maryland Stem Cell Commission Issues Nationwide Request for Applications for New Post-Doctoral Fellowship Grants
8. CCPM Issues Statement on FDAs GIVE Initiative
9. Symmetry Medical Discloses Accounting Issues at Sheffield, UK Operating Unit and Possible Restatement
10. CalbaTech Issues Update; Beginning Training for Adult Stem Cell Collections in Atlanta
11. HHS Issues First Department-Wide Report on Personalized Health Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... University of Manchester have generated a new star-shaped molecule made ... its kind ever created. , Known as a ... one for over a quarter of a century and the ... . , Consisting of two molecular triangles, entwined about ... molecules are tiny each triangle is 114 atoms in ...
(Date:9/22/2014)... , Sept. 22, 2014 US demand to ... for specialty biocides is forecast to rise 3.9 percent ... terms, demand is projected to increase 1.3 percent per ... A strong rebound in construction expenditures will support demand ... coatings markets, while growth in consumer spending and manufacturing ...
(Date:9/22/2014)... (PRWEB) September 22, 2014 Invisible ... diagnostics for the food and beverage industries, announced ... be distributed under a non-exclusive agreement by Enartis, ... services. , Enartis, an Esseco Group company headquartered ... winemakers in California and other global markets for ...
(Date:9/22/2014)... September 22, 2014 The US ... mixed note as the Dow Jones Industrial Average finished ... at 4,579.79, down 0.30%. The S&P 500 finished the ... six out of ten sectors finished on a positive ... the day at 751.48, up 0.10%, with the index ...
Breaking Biology Technology:US Biocides Market 2US Biocides Market 3Invisible Sentinel's Test for Wine-Spoilage Microbe to be Distributed by Enartis in Multiple Markets Globally 2Invisible Sentinel's Test for Wine-Spoilage Microbe to be Distributed by Enartis in Multiple Markets Globally 3Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 2Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 3Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 4Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 5
... ST. LOUIS, Oct. 2 /PRNewswire-FirstCall/ -- ... ) has elected Dr. George M. Church as a Director ... Professor of Genetics at the Harvard Medical School and Director ... Dr. Church pioneered technology innovations early in the development of ...
... Host Conference Call-- , CALGARY, Oct. 2 /PRNewswire-FirstCall/ - ... it has reached an agreement with the U.S. Food ... (SPA) process for the design of a Phase 3 ... in patients with platinum-refractory head and neck cancers. The ...
... ... the recipients of the 2009 Orange County Emerging Growth Awards, recognizing companies headquartered in ... significant growth over the last 12 months and that have made a positive impact ... ...
Cached Biology Technology:Sigma-Aldrich Elects George M. Church as Director 2Oncolytics Biotech(R) Inc. Reaches Special Protocol Assessment Agreement with the FDA on Design of Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers 2Oncolytics Biotech(R) Inc. Reaches Special Protocol Assessment Agreement with the FDA on Design of Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers 3Oncolytics Biotech(R) Inc. Reaches Special Protocol Assessment Agreement with the FDA on Design of Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers 4Oncolytics Biotech(R) Inc. Reaches Special Protocol Assessment Agreement with the FDA on Design of Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers 5Southern California Venture Network Announces Recipients of the 2009 Orange County Emerging Growth Awards 2Southern California Venture Network Announces Recipients of the 2009 Orange County Emerging Growth Awards 3Southern California Venture Network Announces Recipients of the 2009 Orange County Emerging Growth Awards 4
(Date:9/22/2014)... -- NXT-ID, Inc. (NASDAQ: NXTD ), a ... market, issues the following corporate shareholder update following the ... Letter from the CEO : ... joined the NASDAQ to support ramping of production of ... authentication products and services. This strategic achievement positions NXT-ID to ...
(Date:9/21/2014)... (black-eyed peas) is a fascinating example of how science ... the story of the scientist behind the research. ... the 21st Century to serve as an accessible summary ... recently published by the Crop Science Society of America, ... , Singh has devoted his life,s work to solving ...
(Date:9/21/2014)... immune T cells may have the ability to trigger ... study led by King,s College London. Although their immune ... may still be able to mount a strong immune ... Nature Medicine . , Our immune system is made ... neutrophils which play an important role in the frontline ...
Breaking Biology News(10 mins):NXT-ID Issues Shareholder Corporate Update 2NXT-ID Issues Shareholder Corporate Update 3NXT-ID Issues Shareholder Corporate Update 4Immune system of newborn babies is stronger than previously thought 2
... release is available in German . ... travel of tomorrow is meant to become quieter, cleaner and ... to accomplish just that as part of the EU ... technical aspects of air travel to the test, evaluating and ...
... study has highlighted the sensitivity of Australia,s species and ... ways of thinking about biodiversity conservation. ,Climate change ... natural landscapes by 2030, lead researcher, CSIRO,s Dr Michael ... be very significant and widespread. Many of the environments ...
... a leading software company in the clinical ... Next Generation Biobanking software platform for biomarker-based ... and academic research centers involved in biomarker-based ... effectively conduct externalized, science-driven collaborative studies. ...
Cached Biology News:Fraunhofer supports continuation of 'Clean Sky' program 2Major changes needed to protect Australia's species and ecosystems 2BioFortis Inc., Introduces Next Generation Biobanking Software Platform for Biomarker-Based Clinical Research 2
Takara's Mutan-Super Express Km Kit is designed to achieve site-directed mutagenesis in just one day. It is based on Oligonucleotide-directed Dual Amber (ODA) method, using the advantages of LA (Long...
... 4 deuterium atoms at the 9, 10, 12, ... as an internal standard for the quantification of ... produced by incubation of linoleic acid with plant ... inhibit the adhesion of tumor cells to the ...
... and TriEx Insect Cell Medium are recommended ... This cell/medium combination has been selected based ... protein expression levels observed specifically with baculoviruses ... that our Ready-Plaque Sf9 Cells and BacVector ...
...
Biology Products: